# Alliance for Clinical Trials in Oncology

Source: https://onco.cc/companies/alliance-oncology/  
OnCo record `alliance-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

US cooperative group formed from CALGB, ACOSOG, and NCCTG; running OptimICE-pCR, which asks whether TNBC patients with a complete response still need a year of immunotherapy.

## Summary

The Alliance for Clinical Trials in Oncology, based in Chicago, is the US cooperative group formed in 2011 from CALGB, ACOSOG and NCCTG, and a member of the NCI National Clinical Trials Network. Its trials include CALGB 40603, which tested carboplatin in triple-negative breast cancer, Z0011, which showed sentinel node biopsy could replace axillary dissection in selected patients, and A012103, the OptimICE-pCR trial asking whether TNBC patients with a pathologic complete response still need a year of pembrolizumab; ATOMIC and CABINET are also in OnCo, with Alan P. Venook and Evanthia Galanis among the people linked. OnCo connects it to bottlenecks on slow enrolment and the exclusion of older patients, and to ideas for a permanent surgical trials network. Whether de-escalation trials can recruit when the default is more treatment is its standing question. Its programmes are listed in the notes.

## Fields

- Kind: Company
- Last checked: 2026-09-06
- Also known as: Alliance; Cancer and Leukemia Group B; CALGB; Alliance Foundation Trials; ACOSOG; NCCTG
- Tags: cooperative-group
- HQ: Chicago, IL
- Type: cooperative-group
- Website: https://www.allianceforclinicaltrialsinoncology.org

## Notes

- NCTN cooperative group
- OptimICE-pCR
- Breast surgical de-escalation (Z0011)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Alliance_for_Clinical_Trials_in_Oncology
- Official website: https://www.allianceforclinicaltrialsinoncology.org

## Connected records

- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Craniopharyngioma](https://onco.cc/cancers/craniopharyngioma/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Sentinel lymph node biopsy](https://onco.cc/technologies/sentinel-node/)
- institutions: [Duke Cancer Institute](https://onco.cc/institutions/duke-cancer-institute/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- trials: [ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)](https://onco.cc/trials/alchemist/), [Alliance A071401](https://onco.cc/trials/a071401/), [Alliance N0574 (NCCTG N0574)](https://onco.cc/trials/alliance-n0574/), [ATOMIC (Alliance A021502)](https://onco.cc/trials/atomic/), [CABINET (Alliance A021602)](https://onco.cc/trials/cabinet/), [CALGB 140503 (Alliance)](https://onco.cc/trials/calgb-140503/), [CALGB 40603 (Alliance)](https://onco.cc/trials/calgb-40603/), [CODEL](https://onco.cc/trials/codel/), [Lung-MAP (SWOG S1400 and S1900)](https://onco.cc/trials/lung-map/), [OptimICE-pCR (A012103)](https://onco.cc/trials/optimice-pcr/), [PROSPECT (Alliance N1048)](https://onco.cc/trials/prospect/)
- people: [Alan P. Venook](https://onco.cc/people/alan-venook/), [Evanthia Galanis](https://onco.cc/people/evanthia-galanis/)
- bottlenecks: [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Trials enrol too few, too slowly](https://onco.cc/bottlenecks/b-trial-enrolment/)
- ideas: [A permanently funded international network for randomised cancer surgery trials](https://onco.cc/ideas/idea-fund-surgical-trials-network/), [A statutory minimum share of public trial money for surgery and radiotherapy](https://onco.cc/ideas/idea-fund-non-drug-trial-quota/)
- roadmaps: [Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on](https://onco.cc/roadmaps/trial-modernisation-roadmap/)
- companies: [Austrian Breast & Colorectal Cancer Study Group](https://onco.cc/companies/abcsg/), [ETOP IBCSG Partners Foundation](https://onco.cc/companies/etop-ibcsg/)
- key papers: [Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations](https://onco.cc/key-papers/paper-a071401-brastianos-jco-2023/)

---
JSON: https://onco.cc/api/v1/entities/alliance-oncology.json